Viridian Therapeutics, Inc.
NASDAQViridian Therapeutics heads into the summer with a striking contradiction at its core: options traders are the most bullish they have been in months, yet short sellers are quietly adding to one of the heaviest positions in the biotech complex. The options signal is the sharpest data point this week. The put/call ratio has collapsed to 0.077 — nearly at the 52-week low of 0.075 and…
Snapshot as of 6 Aug 2026
Viridian Therapeutics heads into the summer with a striking contradiction at its core: options traders are the most bullish they have been in months, yet short sellers are quietly adding to one of the heaviest…
Viridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VRDN — free to start on ORTEX.
Sign up for free →Open VRDN on ORTEX